As the COVID-19 situation worsens in the UK, Novavax has come up with a vaccine that is believed to be 89% effective for the patients. On the other hand, Pfizer’s coronavirus vaccine is 94% effective.
The UK is facing trouble with a mutation in the COVID-19 virus that has hit the country recently, and they are trying to find a suitable vaccine to counter it.
Prime Minister Boris Johnson is happy that Novavax has developed the vaccine for UK citizens.
The international community is in desperate need to secure a vaccine, and it is a good sign that Novavax is now developing a vaccine to address the issue.
Before the vaccine is administered to the local people, it needs to be approved by the Medicines and Healthcare Product Regulatory Agency. If the company can secure this approval, they can roll out the vaccine in the second half of this year.
The United Kingdom has so far allowed three different companies to vaccinate people across the country, including Pfizer, BioNTech, and Moderna and they are rolling out the vaccines on a daily basis.
Out of all the vaccines available in the market, the most effective one with 94% effectiveness is produced by Pfizer. They managed to secure the official rollout from the United States as well.
The Novavax vaccine was also tested in South Africa, but it was only 60% effective. The Novavax vaccine can be stored at normal temperature.
As the situation stands, the number of COVID-19 cases is going up, but the premier is confident that the Novavax vaccine will help contain the pandemic in the country.
If the country can roll out the Novavax vaccine, it will be able to secure more vaccines for its citizens. But Novavax still has to go through a lot of approvals to make sure that they are ruling out the vaccine that is more effective and safe.
